Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II.

scientific article

Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1021/JM0111043
P698PubMed publication ID11960491

P2093author name stringEvi Kostenis
Michael Kurz
Alain Fournier
Thomas Klabunde
Stefanie Flohr
Alexandre Brkovich
P433issue9
P407language of work or nameEnglishQ1860
P921main subjectvirtual screeningQ4112105
P304page(s)1799-1805
P577publication date2002-04-01
P1433published inJournal of Medicinal ChemistryQ900316
P1476titleIdentification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II.
P478volume45

Reverse relations

cites work (P2860)
Q73313937A Combinatorial Scaffold Approach Based upon a Multicomponent Reaction
Q40703439A new ligand for the urotensin II receptor
Q28478109A novel structural framework for α(1A/D)-adrenoceptor selective antagonists identified using subtype selective pharmacophores
Q37737587A rat brain atlas of urotensin-II receptor expression and a review of central urotensin-II effects
Q34985885An overview on GPCRs and drug discovery: structure-based drug design and structural biology on GPCRs
Q42667921Behavioral effects of urotensin-II centrally administered in mice
Q28260943Biochemical and functional characterization of high-affinity urotensin II receptors in rat cortical astrocytes
Q76383741Cardiovascular actions of human urotensin II--considerations for hypertension
Q54708765Cellular distribution of GPR14 and the positive inotropic role of urotensin II in the myocardium in adult rat.
Q34479147Comparative genomics provides evidence for close evolutionary relationships between the urotensin II and somatostatin gene families
Q42069892Construction of a sequence motif characteristic of aminergic G protein-coupled receptors
Q42004371De novo molecular modeling and biophysical characterization of Manduca sexta eclosion hormone
Q31035828Directed sorting approach for the synthesis of large combinatorial libraries of discrete compounds
Q90650682Discovery of Novel Glucagon Receptor Antagonists Using Combined Pharmacophore Modeling and Docking
Q35033297Emerging roles for orphan G-protein-coupled receptors in the cardiovascular system
Q37388375G protein-coupled receptors: in silico drug discovery in 3D.
Q35047377Identification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines
Q35997019In silico design and analysis of a new hyperglycosylated analog of erythropoietin to improve drug efficacy
Q35995265In silico pharmacology for drug discovery: applications to targets and beyond
Q36840592In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
Q48675996Localization of the urotensin II receptor in the rat central nervous system
Q51552963New QSAR prediction models derived from GPCR CB2-antagonistic triaryl bis-sulfone analogues by a combined molecular morphological and pharmacophoric approach.
Q44114224New insight into the binding mode of peptides at urotensin-II receptor by Trp-constrained analogues of P5U and urantide
Q26772046Pharmacophore Models and Pharmacophore-Based Virtual Screening: Concepts and Applications Exemplified on Hydroxysteroid Dehydrogenases
Q41981084Photolabelling the rat urotensin II/GPR14 receptor identifies a ligand-binding site in the fourth transmembrane domain.
Q46248274Predicted ligands for the human urotensin-II G protein-coupled receptor with some experimental validation
Q42397196Prediction of the three-dimensional structure for the rat urotensin II receptor, and comparison of the antagonist binding sites and binding selectivity between human and rat receptors from atomistic simulations
Q36902874Role of urotensin II and its receptor in health and disease
Q37737495Role of urotensin II in health and disease
Q34012132Small molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3
Q58855647Structure-Activity Study of the Peptides P5U and Urantide by the Development of Analogues Containing Uncoded Amino Acids at Position 9
Q44564935Structure-activity relationships of human urotensin II and related analogues on rat aortic ring contraction
Q40644520The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors
Q36760529Therapeutic potential of blockade of the urotensin II system in systemic hypertension
Q54414485Urantide conformation and interaction with the urotensin-II receptor.
Q38093584Urotensin-II Ligands: An Overview from Peptide to Nonpeptide Structures
Q35779239Urotensin-II and the cardiovascular system--the importance of developing modulators
Q50992476Urotensin-II peptidomimetic incorporating a non-reducible 1,5-triazole disulfide bond reveals a pseudo-irreversible covalent binding mechanism to the urotensin G-protein coupled receptor.
Q39039151Urotensin-II receptor is over-expressed in colon cancer cell lines and in colon carcinoma in humans.

Search more.